What Are Retatrutide's Side Effects?
Last updated: January 2026
Quick Answer
Similar to tirzepatide: nausea (most common), diarrhea, constipation, decreased appetite, vomiting. In Phase 2, 77% of patients on the highest dose reported GI side effects vs 72% for tirzepatide — slightly higher but manageable. Effects typically peak in the titration phase.
What Are Retatrutide's Side Effects
Similar to tirzepatide: nausea (most common), diarrhea, constipation, decreased appetite, vomiting. In Phase 2, 77% of patients on the highest dose reported GI side effects vs 72% for tirzepatide — slightly higher but manageable. Effects typically peak in the titration phase.
Understanding GLP-1 side effects helps you prepare for and manage them effectively. Most side effects are gastrointestinal in nature and resolve within the first 4-8 weeks as your body adjusts to the medication. Slow dose titration is the most effective strategy for minimizing side effects.
Managing Side Effects Effectively
The gradual dose escalation schedule built into GLP-1 treatment protocols exists specifically to minimize side effects. Starting at the lowest dose and increasing every 4 weeks gives your body time to adjust. If side effects are severe, your provider can slow the titration schedule.
Practical Tips
- Eat smaller, more frequent meals to reduce nausea
- Stay well hydrated with at least 64 ounces of water daily
- Avoid high-fat, greasy, and heavily processed foods
- Keep ginger tea, peppermint, or anti-nausea medication available
- Report any concerning symptoms to your healthcare provider promptly
It is important to distinguish between common, manageable side effects and rare but serious conditions that require immediate medical attention. Always err on the side of contacting your provider if you are unsure about any symptom.
Related Questions
What is Retatrutide?
Retatrutide is Eli Lilly's next-generation weight loss drug in Phase 3 trials. It activates three receptors simultaneously (GLP-1, GIP, and glucagon), producing stronger weight loss than any currently approved medication. Phase 2 showed 24.2% average weight loss over 48 weeks.
Retatrutide vs Tirzepatide: Which is More Effective?
Phase 2 data shows retatrutide (24.2% weight loss) outperforms tirzepatide (20.9%). 58% of retatrutide patients lost ≥20% body weight versus 57% for tirzepatide at highest doses. Retatrutide adds a glucagon receptor component that enhances fat burning and metabolic rate.